Company intelligence / Profile preview

3ive Labs

Ownership: Private
Development stage: Phase 3

Overview

The company’s lead program is the JuxtaFlow Renal Assist Device (RAD), which recently received FDA Investigational Device Exemption approval for a pivotal trial. The GRADIENT study will evaluate its safety and efficacy in preserving renal function among high-risk cardiac surgery patients. No commercial or late-stage results are yet available.

Therapeutic areas: CardiovascularNephrology
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

JuxtaFlow RAD

Phase 3

Indications: Renal insufficiency during cardiac surgery, Acute kidney injury

Beyond the preview

Go deeper on 3ive Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3ive Labs.

Explore the full profile